Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 27:2020:8120398.
doi: 10.1155/2020/8120398. eCollection 2020.

Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes

Affiliations

Pharmacokinetics after Periocular Methylprednisolone Sodium Succinate Injection in Rabbit Eyes

Hua-Yi Lu et al. Evid Based Complement Alternat Med. .

Abstract

The present study aimed to determine the pharmacokinetics and distribution of methylprednisolone sodium succinate (MPSS) and its metabolic product methylprednisolone (MP) in plasma and ocular tissues after periocular injection of MPSS in rabbit eyes. Forty-eight healthy New Zealand white rabbits were randomly divided into 12 groups, including the control group and 11 MPSS-treated groups sampling at different time points. Rabbits in the MPSS-treated groups underwent left eye periocular injection of MPSS (10 mg). The pharmacokinetics of MPSS and MP in plasma and ocular tissues (including aqueous humor, vitreous, iris, lens, sclera, optic nerve, and choroid and retina) were investigated by liquid chromatography tandem mass spectrometry (LC-MS/MS). After periocular injection, the time of maximum concentration (T max) of MPSS ranged from 0.25 h to 1 h in ocular tissues and was 0.25 h in plasma. T max of MP in ocular tissues ranged from 0.5 h to 6 h, and T max of MP in plasma was 0.5 h. The maximum concentration (C max) of MPSS and MP and the area under the curve (AUC0-t ) in ocular tissues from high to low was sclera, optic nerve, choroid and retina, iris, and lens. Especially, the concentrations of MPSS and MP in the lens were much lower when compared with the other ocular tissues. After periocular administration, MPSS could be rapidly metabolized to its active constituent MP in the ocular tissues. Also, the MPSS can be delivered effectively into the posterior segment of the eye (choroid and retina), while not easily be absorbed by the lens.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Full scan product ion spectra of [M-H] for MPSS (a), MP (b), and dexamethasone (c).
Figure 2
Figure 2
Representative multiple reaction monitoring chromatograms of MPSS, MP, and dexamethasone in rabbit blood plasma: (a) blank plasma sample; (b) plasma sample spiked with MPSS (0.3 ng/ml), MP (3 ng/ml), and dexamethasone (1000 ng/ml); (c) plasma sample obtained when concentration was highest after administration of MPSS in healthy rabbits (I for MPSS, II for MP, and Ш for dexamethasone).

References

    1. Woods A. C. Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease. American Journal of Ophthalmology. 1950;33(9):1325–1351. doi: 10.1016/0002-9394(50)91827-7. - DOI - PubMed
    1. Lobo A. M., Sobrin L., Papaliodis G. N. Drug delivery options for the treatment of ocular inflammation. Seminars in Ophthalmology. 2010;25(5-6):283–288. doi: 10.3109/08820538.2010.518522. - DOI - PubMed
    1. Jabs D. A., Rosenbaum J. T., Foster C. S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. American Journal of Ophthalmology. 2001;131(5):p. 649. doi: 10.1016/s0002-9394(01)00830-3. - DOI - PubMed
    1. Jabs D. A. Treatment of ocular inflammation. Ocular Immunology and Inflammation. 2004;12(3):163–168. doi: 10.1080/09273940490883671. - DOI - PubMed
    1. Al-Habet S. M., Rogers H. J. Methylprednisolone pharmacokinetics after intravenous and oral administration. British Journal of Clinical Pharmacology. 1989;27(3):285–290. doi: 10.1111/j.1365-2125.1989.tb05366.x. - DOI - PMC - PubMed

LinkOut - more resources